Pfizer and BioNTech to supply Japan with 120 million doses of their BNT162 mRNA-based vaccine candidate
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement with the Ministry of Health, Labour and Welfare (MHLW) in Japan to supply 120 million doses of BNT162 mRNA-based vaccine candidate against SARS-CoV2, subject to clinical success and regulatory approval, beginning in 2021. (Source: World Pharma News)
Source: World Pharma News - July 31, 2020 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Single-shot COVID-19 vaccine protects non-human primates
The development of a safe and effective vaccine will likely be required to end the COVID-19 pandemic. A group of scientists, led by Beth Israel Deaconess Medical Center (BIDMC) immunologist Dan H. Barouch, MD, PhD, now report that a leading candidate COVID-19 vaccine developed at BIDMC in collaboration with Johnson & Johnson raised neutralizing antibodies and robustly protected non-human primates (NHPs) against SARS-CoV-2, the virus that causes COVID-19. (Source: World Pharma News)
Source: World Pharma News - July 31, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Single dose of Johnson & Johnson COVID-19 vaccine candidate demonstrates robust protection in pre-clinical studies
Johnson & Johnson (NYSE: JNJ) (the Company) today announced that its lead vaccine candidate protected against infection with SARS-CoV-2, the virus that causes COVID-19, in pre-clinical studies. The data, published in Nature, show the Company's investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as demonstrated by "neutralizing antibodies," successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates (NHPs) in the pre-clinical study. (Source: World Pharma News)
Source: World Pharma News - July 30, 2020 Category: Pharmaceuticals Tags: Featured Johnson & Business and Industry Source Type: news

Immunoprotein impairs Sars-Cov-2
A protein produced by the human immune system can strongly inhibit corona viruses, including Sars-Cov-2, the pathogen causing Covid-19. An international team from Germany, Switzerland and the USA successfully showed that the LY6E-Protein prevents coronaviruses from causing an infection. (Source: World Pharma News)
Source: World Pharma News - July 29, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer and BioNTech choose lead mRNA vaccine candidate against COVID-19 and commence pivotal Phase 2/3 global study
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the start of a global (except for China) Phase 2/3 safety and efficacy clinical study to evaluate a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine program against SARS-CoV-2. (Source: World Pharma News)
Source: World Pharma News - July 28, 2020 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Experimental COVID-19 vaccine protects upper and lower airways in nonhuman primates
Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2, report scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. SARS-CoV-2 is the virus that causes COVID-19. (Source: World Pharma News)
Source: World Pharma News - July 28, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer and BioNTech announce an agreement with U.S. Government for up to 600 million doses of mRNA-based vaccine aandidate against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of Defense to meet the U.S. government's Operation Warp Speed program goal to begin delivering 300 million doses of a vaccine for COVID-19 in 2021. (Source: World Pharma News)
Source: World Pharma News - July 27, 2020 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Pfizer and BioNTech announce agreement with the United Kingdom for 30 million doses of mRNA-based vaccine candidate against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, currently in development, subject to clinical success and regulatory approval. Financial details of the agreement were not disclosed, but the terms were based on the timing of delivery and the volume of doses. (Source: World Pharma News)
Source: World Pharma News - July 27, 2020 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Another mRNA-based vaccine candidate protects animals against SARS-CoV-2
An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and non-human primates, researchers report on July 23rd in the journal Cell. Two injections of the vaccine were sufficient to induce robust immunity, completely preventing SARS-CoV-2 infection in mice. (Source: World Pharma News)
Source: World Pharma News - July 24, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

COVID-19 vaccine innovation could dramatically speed up worldwide production
Responding to a need to quickly develop billions of doses of lifesaving COVID-19 vaccines, a scientific team at The University of Texas at Austin has successfully redesigned a key protein from the coronavirus, and the modification could enable much faster and more stable production of vaccines worldwide. (Source: World Pharma News)
Source: World Pharma News - July 23, 2020 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Neutralizing antibodies isolated from COVID-19 patients may suppress virus
Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing the SARS-CoV-2 virus. These antibodies could be produced in large quantities by pharmaceutical companies to treat patients, especially early in the course of infection, and to prevent infection, particularly in the elderly. (Source: World Pharma News)
Source: World Pharma News - July 22, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

GSK and CureVac announce strategic mRNA technology collaboration
GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements GSK's existing mRNA capabilities with CureVac’s integrated mRNA platform. (Source: World Pharma News)
Source: World Pharma News - July 21, 2020 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial
Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-CoV-2 virus in all evaluated participants. COV001 is a blinded, multi-centre, randomised controlled Phase I/II trial with 1,077 healthy adult participants, aged 18-55 years. It assessed a single dose of AZD1222 against a comparator meningococcal conjugate vaccine, MenACWY. (Source: World Pharma News)
Source: World Pharma News - July 20, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19
Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms of COVID-19 - a critical need in the absence of a vaccine or curative treatment. Inflammation and respiratory problems linked to COVID-19 can cause severe medical complications and can lead to death in some people, putting immense strain on fragile healthcare systems. (Source: World Pharma News)
Source: World Pharma News - July 17, 2020 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Scientists uncover SARS-CoV-2-specific T cell immunity in recovered COVID-19 and SARS patients
The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore General Hospital (SGH) and National Centre for Infectious Diseases (NCID) was published in Nature. (Source: World Pharma News)
Source: World Pharma News - July 16, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Common FDA-approved drug may effectively neutralize virus that causes COVID-19
A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in Antiviral Research. SARS-CoV-2, the virus that causes COVID-19, uses a surface spike protein to latch onto human cells and initiate infection. (Source: World Pharma News)
Source: World Pharma News - July 15, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer and BioNTech granted FDA Fast Track designation for two investigational mRNA-based vaccine candidates against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being developed to help protect against SARS-CoV-2 (the virus that causes COVID-19), received Fast Track designation from the U.S. Food and Drug Administration (FDA). (Source: World Pharma News)
Source: World Pharma News - July 14, 2020 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Drug linked to 45% lower risk of dying among COVID-19 patients on ventilators
Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be out of the hospital or off a ventilator one month after treatment, compared with those who didn't receive the drug, according to a new study by a team from the University of Michigan. (Source: World Pharma News)
Source: World Pharma News - July 13, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Sanofi and Regeneron provide update on Kevzara ® (sarilumab) Phase 3 U.S. trial in COVID-19 patients
Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone (placebo). (Source: World Pharma News)
Source: World Pharma News - July 10, 2020 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Researchers call for worldwide biosurveillance network to protect from diseases
The emergence of COVID-19 is a powerful reminder of how unchecked wildlife trade can lead to the spillover spread of viruses between wildlife and humans. Understanding that wholesale bans on trade can affect community livelihoods and food security, the pandemic underscores the need for widespread pathogen screening and monitoring to better understand, predict and contain outbreaks in wildlife and humans. (Source: World Pharma News)
Source: World Pharma News - July 9, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New study supports remdesivir as COVID-19 treatment
The news about remdesivir, the investigational anti-viral drug that has shown early promise in the fight against COVID-19, keeps getting better. This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus. (Source: World Pharma News)
Source: World Pharma News - July 9, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Neutralizing antibodies in the battle against COVID-19
An important line of defence in the fight against the new corona virus SARS-CoV-2 is the formation of neutralising antibodies. These can eliminate the intruders and have great potential to be used for prevention and treatment of SARS-CoV-2 infection. A team of researchers led by Prof. Florian Klein (Cologne University Hospital) and the German Center for Infection Research (DZIF) has further elucidated how these antibodies develop and has isolated potent SARS-CoV-2 neutralizing antibodies. (Source: World Pharma News)
Source: World Pharma News - July 8, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Remdesivir can save more lives where ICUs are overwhelmed
Amid news that the United States has bought up virtually the entire global supply of remdesivir, a new Boston University School of Public Health (BUSPH) study outlines how the drug could save lives in countries with less hospital capacity, such as South Africa, where COVID-19 is beginning to overwhelm intensive care units (ICUs). (Source: World Pharma News)
Source: World Pharma News - July 7, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

GSK and Medicago announce collaboration to develop a novel adjuvanted COVID-19 candidate vaccine
GSK and Medicago announced a collaboration to develop and evaluate a COVID-19 candidate vaccine combining Medicago's recombinant Coronavirus Virus-Like Particles (CoVLP) with GSK's pandemic adjuvant system. CoVLPs mimic the structure of the virus responsible for COVID-19 disease, allowing them to be recognised by the immune system. (Source: World Pharma News)
Source: World Pharma News - July 7, 2020 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Using Epo against COVID-19
Erythropoietin (Epo) is actually a medication for anaemia. According to researchers at the Max Planck Institute of Experimental Medicine in Göttingen, the doping agent Epo could also be effective against COVID-19. The growth factor could mitigate severe disease progression and protect patients from long-term neurological effects when the Sars-CoV-2 virus attacks the brain. (Source: World Pharma News)
Source: World Pharma News - July 6, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Merck initiates first clinical trial of TLR7 and 8 inhibitor as a potential treatment for severe symptoms of COVID-19 infection
Merck, a leading science and technology company, announced the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug application (IND) for M5049 for the treatment of patients with Covid-19 pneumonia. Merck will initiate a Phase II randomized, controlled clinical study evaluating the safety and efficacy of M5049 in this patient population. (Source: World Pharma News)
Source: World Pharma News - July 3, 2020 Category: Pharmaceuticals Tags: Featured Merck Group Business and Industry Source Type: news

Novartis resolves legacy litigation matters, finalizing settlement of speaker program litigation with Government in the US
Novartis has finalized its previously disclosed agreement with the US Attorney's Office for the Southern District of New York, the New York State Attorney General, and relator Oswald Bilotta resolving a civil suit challenging speaker programs and other promotional events conducted from 2002 through 2011 by Novartis Pharmaceuticals Corporation in the US. (Source: World Pharma News)
Source: World Pharma News - July 2, 2020 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Newer variant of COVID-19-causing virus dominates global infections
Research out today in the journal Cell shows that a specific change in the SARS-CoV-2 coronavirus virus genome, previously associated with increased viral transmission and the spread of COVID-19, is more infectious in cell culture. The variant in question, D614G, makes a small but effective change in the virus's 'Spike' protein, which the virus uses to enter human cells. (Source: World Pharma News)
Source: World Pharma News - July 2, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Pfizer and BioNTech announce early positive data from an ongoing Phase 1/2 study of mRNA-based vaccine candidate against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic. The BNT162 program is evaluating at least four experimental vaccines, each of which represents a unique combination of mRNA format and target antigen. (Source: World Pharma News)
Source: World Pharma News - July 1, 2020 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Researchers identify multiple molecules that shut down SARS-Cov-2 polymerase reaction
SARS-CoV-2, the coronavirus causing the global COVID-19 pandemic, uses a protein called polymerase to replicate its genome inside infected human cells. Terminating the polymerase reaction will stop the growth of the coronavirus, leading to its eradication by the human host's immune system. (Source: World Pharma News)
Source: World Pharma News - July 1, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Whole-town study reveals more than 40% of COVID-19 infections had no symptoms
A study of COVID-19 in the quarantined Italian town of Vò, where most of the population was tested, reveals the importance of asymptomatic cases. The authors of the new research, from the University of Padova and at Imperial College London, published today in Nature, suggest asymptomatic or pre-symptomatic people are an important factor in the transmission of COVID-19. (Source: World Pharma News)
Source: World Pharma News - June 30, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA Takes Action to Help Facilitate Timely Development of Safe, Effective COVID-19 Vaccines
Today, the U.S. Food and Drug Administration took important action to help facilitate the timely development of safe and effective vaccines to prevent COVID-19 by providing guidance with recommendations for those developing COVID-19 vaccines for the ultimate purpose of licensure. (Source: World Pharma News)
Source: World Pharma News - June 30, 2020 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Even in the worst COVID-19 cases, the body launches immune cells to fight back
A new study from researchers at La Jolla Institute for Immunology (LJI) and Erasmus University Medical Center (Erasmus MC) shows that even the sickest COVID-19 patients produce T cells that help fight the virus. The study offers further evidence that a COVID-19 vaccine will need to elicit T cells to work alongside antibodies. (Source: World Pharma News)
Source: World Pharma News - June 29, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Existing drugs can prevent SARS-CoV-2 from hijacking cells
An international team of researchers has analysed how SARS-CoV-2, the virus that causes COVID-19, hijacks the proteins in its target cells. The research, published in the journal Cell, shows how the virus shifts the cell's activity to promote its own replication and to infect nearby cells. The scientists also identified seven clinically approved drugs that could disrupt these mechanisms, and recommend that these drugs are immediately tested in clinical trials. (Source: World Pharma News)
Source: World Pharma News - June 29, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Lilly begins world's first study of a potential COVID-19 antibody treatment in humans
Eli Lilly and Company (NYSE: LLY) announced patients have been dosed in the world's first study of a potential antibody treatment designed to fight COVID-19. This investigational medicine, referred to as LY-CoV555, is the first to emerge from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. (Source: World Pharma News)
Source: World Pharma News - June 26, 2020 Category: Pharmaceuticals Tags: Featured Eli Lilly and Company Business and Industry Source Type: news

GSK COVID-19 vaccine development collaboration with Clover Biopharmaceuticals begins clinical trials
GSK's scientific collaboration with Clover Pharmaceuticals to develop an adjuvanted COVID-19 vaccine has entered into human clinical trials. Clover announced the initiation of a Phase 1 clinical study evaluating the company’s COVID-19 S-Trimer vaccine (SCB-2019) in combination with GSKs pandemic adjuvant system. (Source: World Pharma News)
Source: World Pharma News - June 25, 2020 Category: Pharmaceuticals Tags: Featured GlaxoSmithKline Business and Industry Source Type: news

Study is first to identify potential therapeutic targets for COVID-19
A team from Lawson Health Research Institute and Western University are the first in the world to profile the body's immune response to COVID-19. By studying blood samples from critically ill patients at London Health Sciences Centre (LHSC), the research team identified a unique pattern of six molecules that could be used as therapeutic targets to treat the virus. The study is published this week in Critical Care Explorations. (Source: World Pharma News)
Source: World Pharma News - June 25, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges
Novartis revealed the healthcare and pharma industry has emerged as a desired career destination for tech talent during the COVID-19 pandemic, in the Powerful Pairing research report launched today. The research - which covered 2,502 tech professionals in the US, UK, Germany, China and India, conducted between May and June 2020 - targeted respondents from a variety of sectors and organizations with the objective to study perception shifts of the industry in the wake of the global COVID-19 pandemic. (Source: World Pharma News)
Source: World Pharma News - June 24, 2020 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

FDA announces first of its kind pilot program to communicate patient reported outcomes from cancer clinical trials
The U.S. Food and Drug Administration launched Project Patient Voice, an initiative of the FDA’s Oncology Center of Excellence (OCE). Through a new website, Project Patient Voice creates a consistent source of publicly available information describing patient-reported symptoms from cancer trials for marketed treatments. (Source: World Pharma News)
Source: World Pharma News - June 24, 2020 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Sanofi and Translate Bio expand collaboration to develop mRNA vaccines across all infectious disease areas
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, have agreed to expand their existing 2018 collaboration and license agreement to develop mRNA vaccines for infectious diseases. (Source: World Pharma News)
Source: World Pharma News - June 23, 2020 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Initial COVID-19 infection rate may be 80 times greater than originally reported
Many epidemiologists believe that the initial COVID-19 infection rate was undercounted due to testing issues, asymptomatic and alternatively symptomatic individuals, and a failure to identify early cases. Now, a new study from Penn State estimates that the number of early COVID-19 cases in the U.S. may have been more than 80 times greater and doubled nearly twice as fast as originally believed. (Source: World Pharma News)
Source: World Pharma News - June 23, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Novartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research efforts
Novartis has made the decision to stop and discontinue its sponsored HCQ clinical trial for COVID-19 due to acute enrollment challenges that have made trial completion infeasible. The recruitment challenge facing our HCQ trial has made it unlikely that the clinical team will be able to collect meaningful data in a reasonable timeframe to determine the effectiveness of HCQ in treating patients with COVID-19. (Source: World Pharma News)
Source: World Pharma News - June 22, 2020 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Wearable Injectors and Connected Devices Conference 2020
7 - 8 October 2020, London, United Kingdom. The global wearable devices market size is expected to reach a value of $62.82 billion USD by 2025 with time dependent delivery, improved patient experience and adherence and large volume administration with minimal injection pain and being key factors driving the market. (Source: World Pharma News)
Source: World Pharma News - June 22, 2020 Category: Pharmaceuticals Tags: Featured Events Source Type: news

Bayer supports "The Challenge Initiative" of Johns Hopkins Bloomberg School of Public Health with 10 million USD
Today Bayer announced the support of "The Challenge Initiative" ("TCI" hereafter) with a payment of 10 million USD. Hosted at the Johns Hopkins Bloomberg School of Public Health, the initiative provides women and girls living in urban poverty in cities in Africa and Asia with family planning and reproductive health solutions. (Source: World Pharma News)
Source: World Pharma News - June 19, 2020 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Mayo finds convalescent plasma safe for diverse patients with COVID-19
Mayo Clinic researchers and collaborators have found investigational convalescent plasma to be safe following transfusion in a diverse group of 20,000 patients. The findings - from the U.S. Food and Drug Administration's Expanded Access Program for COVID-19 - are reported in Mayo Clinic Proceedings. (Source: World Pharma News)
Source: World Pharma News - June 18, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Researchers identify potent antibody cocktail to treat COVID-19
Researchers at the University of Maryland School of Medicine (UMSOM) evaluated several human antibodies to determine the most potent combination to be mixed in a cocktail and used as a promising anti-viral therapy against the virus that causes COVID-19. Their research, conducted in collaboration with scientists at Regeneron Pharmaceuticals, was published in the journal Science. (Source: World Pharma News)
Source: World Pharma News - June 18, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Sanofi invests to make France its world class center of excellence in vaccine research and production
Sanofi detailed plans on how the Company will make significant investments in France to increase its vaccines research and production capacities, and contribute in responding to future pandemic risks. Aligned with its corporate strategy presented last December, Sanofi will invest €610 million to create a new production site and research center in France with both dedicated to vaccines. (Source: World Pharma News)
Source: World Pharma News - June 17, 2020 Category: Pharmaceuticals Tags: Featured Sanofi Business and Industry Source Type: news

Nanosponges could intercept coronavirus infection
Nanoparticles cloaked in human lung cell membranes and human immune cell membranes can attract and neutralize the SARS-CoV-2 virus in cell culture, causing the virus to lose its ability to hijack host cells and reproduce. The first data describing this new direction for fighting COVID-19 were published on June 17 in the journal Nano Letters. The "nanosponges" were developed by engineers at the University of California San Diego and tested by researchers at Boston University. (Source: World Pharma News)
Source: World Pharma News - June 17, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19
In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Over 11,500 patients have been enrolled from over 175 NHS hospitals in the UK. (Source: World Pharma News)
Source: World Pharma News - June 16, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Super-potent human antibodies protect against COVID-19 in animal tests
A team led by Scripps Research has discovered antibodies in the blood of recovered COVID-19 patients that provide powerful protection against SARS-CoV-2, the coronavirus that causes the disease, when tested in animals and human cell cultures. The research, published today in Science, offers a paradigm of swift reaction to an emergent and deadly viral pandemic, and sets the stage for clinical trials and additional tests of the antibodies, which are now being produced as potential treatments and preventives for COVID-19. (Source: World Pharma News)
Source: World Pharma News - June 15, 2020 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news